Enhanced EPR directed and Imaging guided Photothermal Therapy using Vitamin E Modified Toco-Photoxil

Chauhan, Deepak S and Bukhari, Amirali B and Ravichandran, Gayathri and Gupta, Ramkrishn and George, Liya and Poojari, Radhika and Ingle, Aravind and Rengan, Aravind Kumar and Shanavas, Asifkhan and Srivastava, Rohit and De, Abhijit (2018) Enhanced EPR directed and Imaging guided Photothermal Therapy using Vitamin E Modified Toco-Photoxil. Scientific Reports, 8 (1). pp. 1-15. ISSN 2045-2322

[img]
Preview
Text
Scientific Reports_8_1_1-15_2018.pdf - Published Version

Download (4MB) | Preview

Abstract

Herein we report synthesis, characterization and preclinical applications of a novel hybrid nanomaterial Toco-Photoxil developed using vitamin E modified gold coated poly (lactic-co-glycolic acid) nanoshells incorporating Pgp inhibitor d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) as a highly inert and disintegrable photothermal therapy (PTT) agent. Toco-Photoxil is highly biocompatible, physiologically stable PTT material with an average diameter of 130 nm that shows good passive accumulation (2.3% ID) in solid tumors when delivered systemically. In comparison to its surface modified counterparts such as IR780-Toco-Photoxil, FA-Toco-Photoxil or FA-IR780-Toco-Photoxil accumulation are merely ~0.3% ID, ~0.025% ID and ~0.005% ID in folate receptor (FR) negative and positive tumor model. Further, Toco-Photoxil variants are prepared by tuning the material absorbance either at 750 nm (narrow) or 915 nm (broad) to study optimal therapeutic efficacy in terms of peak broadness and nanomaterial’s concentration. Our findings suggest that Toco-Photoxil tuned at 750 nm absorbance is more efficient (P = 0.0097) in preclinical setting. Toco-Photoxil shows complete passiveness in critical biocompatibility test and reasonable body clearance. High tumor specific accumulation from systemic circulation, strong photothermal conversion and a very safe material property in body physiology makes Toco-Photoxil a superior and powerful PTT agent, which may pave its way for fast track clinical trial in future.

[error in script]
IITH Creators:
IITH CreatorsORCiD
Rengan, Aravind KumarUNSPECIFIED
Item Type: Article
Subjects: Biomedical Engineering
Divisions: Department of Biomedical Engineering
Depositing User: Team Library
Date Deposited: 29 Nov 2018 09:52
Last Modified: 29 Nov 2018 09:52
URI: http://raiith.iith.ac.in/id/eprint/4579
Publisher URL: http://doi.org/10.1038/s41598-018-34898-3
OA policy: http://www.sherpa.ac.uk/romeo/issn/2045-2322/
Related URLs:

Actions (login required)

View Item View Item
Statistics for RAIITH ePrint 4579 Statistics for this ePrint Item